Taken together, new novel cancer therapies may involve modulation of neutrophil function through alterations of the tumor microenvironment by blocking TGF-β activity or enhancing IFN-β activity instead of depleting specific neutrophil subsets such mature and immature low-density neutrophils (LDN) that accumulate continuously with cancer progression (148). This evidence concerns the gene TGFB1 and neoplasm.